Alpha-Gal Syndrome Allergy Market: Rising Tick Exposure and the Diagnostic Landscape

Alpha-gal syndrome is a food allergy associated with the carbohydrate galactose-α-1,3-galactose, which enters the body through tick bites. Patients may react after eating mammalian meat such as beef, pork, or lamb. Polaris Market Research estimates the alpha-gal syndrome allergy market at USD 78.49 million in 2025, rising to USD 84.94 million in 2026 and a projected USD 163.16 million by 2034, at a CAGR of 8.5% from 2026 to 2034. This article reviews the factors behind diagnosis and demand.

A Condition with Delayed Onset

Unlike common food allergies that trigger immediate immune responses, alpha-gal syndrome results in delayed allergic reactions occurring several hours after red meat is consumed. The healthcare system therefore focuses on early detection, patient education, and long-term dietary management. Healthcare providers use blood tests and clinical assessments to confirm alpha-gal sensitivity.

Tick-Borne Diseases Drive Diagnosed Cases

Rising tick-borne diseases are increasing the number of diagnosed alpha-gal syndrome patients. In October 2025, researchers at Virginia Commonwealth University observed a sharp increase in the incidence of the syndrome in the U.S., associated with the rising prevalence of the lone star tick, which is responsible for red meat allergies. The U.S. CDC reported that state and local health departments recorded an average of 46,115 tick-borne disease cases annually between 2019 and 2022. Growing exposure to ticks is expanding the diagnosed patient population and demand for allergy testing services.

Diagnostics and Alpha-Gal Antibody Detection

By offering, diagnostics accounted for approximately 63.5% of the market in 2025, supported by rising clinical testing, improved laboratory capabilities, and growing awareness of alpha-gal antibody detection. Healthcare professionals use blood tests and lab tests to confirm the presence of alpha-gal antibodies. Advances in molecular diagnostics and a focus on biomarker discovery are helping improve early detection. In February 2025, IgGenix identified over 60 specific monoclonal antibodies against alpha-gal from red meat allergy patients using its SEQ SIFTER technology, offering insights for future diagnostic and therapeutic products.

Therapeutics and Hospital Pharmacies

Therapeutics is expected to record the highest CAGR during the forecast period, as doctors recommend drugs to manage allergies and prevent reactions during an allergy attack. By distribution channel, hospital pharmacies accounted for nearly 61.7% of the market in 2025, supported by high demand for emergency care and immediate medical support. Hospitals provide drugs for the management of severe allergic reactions and anaphylaxis.

Regional Picture

North America accounted for the largest regional share, around 41.9% in 2025, driven by the high prevalence of tick-borne diseases, increasing awareness, and advanced diagnostic infrastructure. Europe was the second largest market. In February 2026, the BIOGAL project, led by Spain’s Instituto de Investigación en Recursos Cinegéticos (IREC), set out to advance knowledge and prevention of alpha-gal syndrome by studying tick saliva molecules. Asia Pacific is projected to grow at the fastest CAGR, owing to expanding healthcare infrastructure and rising awareness of rare allergic conditions.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/alpha-gal-syndrome-allergy-market 

Key Players and Recent Developments

The competitive scenario is influenced by ongoing research in allergy diagnostic tools and immunology drugs. Leading companies include Abbott Laboratories, Thermo Fisher Scientific Inc., Quest Diagnostics Inc., Labcorp Holdings Inc., Siemens Healthineers AG, Danaher Corporation, bioMérieux SA, EUROIMMUN Medizinische Labordiagnostika AG, Omega Diagnostics Group PLC, HYCOR Biomedical LLC, Stallergenes Greer International AG, and Allergy Therapeutics PLC. Collaboration between pharmaceutical companies, research institutions, and healthcare providers is supporting innovation in allergy detection and treatment. In February 2026, researchers at the University of Missouri were working to understand the increase in alpha-gal syndrome by analyzing patient data and raising awareness of the condition.

Conclusion

The Alpha-Gal Syndrome Allergy Market is attracting greater attention as awareness of tick-associated allergic reactions to certain mammalian products increases. Improved recognition of symptoms, advances in diagnostic testing, and growing clinical understanding may support demand for specialized healthcare services. Opportunities exist in diagnostic development, patient education, allergy management, and research into disease mechanisms. However, underdiagnosis, limited awareness, complex dietary restrictions, and the absence of a universally established curative treatment present significant challenges. Collaboration among clinicians, researchers, diagnostic providers, and public health organizations will be important. Future market development will depend on better diagnosis, improved management strategies, and continued scientific progress.

More Trending Latest Reports By Polaris Market Research:

SiC Wafer Polishing Market

Zollinger-Ellison Syndrome Treatment Market

Needle Free Iv Connectors Market

Cell & Gene Therapy Bioanalytical Testing Services Market

Zollinger-Ellison Syndrome Treatment Market

Platelet Rich Plasma (PRP) Market

Surimi Market

The Resistant Maltodextrin Market: Unlocking Growth Opportunities and Gaining a Competitive Edge

Pizza Oven Market